AMPK phosphorylates and stabilises copper transporter 1 to synergise metformin and copper chelator for breast cancer therapy.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
02
08
2022
accepted:
15
12
2022
revised:
09
12
2022
pmc-release:
17
02
2024
medline:
5
4
2023
pubmed:
23
2
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
Predominant roles of copper and its transporter, copper transporter 1 (CTR1), in tumorigenesis have been explored recently; however, the upstream regulation of CTR1 and combinational intervention of copper chelators in malignancies remain largely unclear. CRISPR/Cas9-based kinome screening was used to identify the CTR1 upstream kinases. Immunofluorescence assays were utilised to detect CTR1 localisation. In vitro kinase assays and mass spectrometry were performed to detect CTR1 phosphorylation. Ubiquitination assays were performed to validate CTR1 stability. Colony formation, EdU labelling, Annexin V-FITC/PI-based apoptosis assays were carried out to detect the drug effect on cell growth and apoptosis. Xenografted mouse models were employed to investigate drug effects in vivo. We identify that CTR1 undergoes AMPK-mediated phosphorylation, which enhances CTR1 stabilisation and membrane translocation by affecting Nedd4l interaction, resulting in increased oncogenic roles in breast cancer. Importantly, activation of AMPK with its agonist metformin markedly enhances CTR1 levels, and leads to the combinational usage of AMPK agonists and copper chelators for breast cancer treatment. Our findings not only reveal the crosstalk between energy response and copper uptake via AMPK-mediated CTR1 phosphorylation and stability but also highlight the strategy to combat breast cancer by a combination of AMPK agonists and copper chelators. The connection between energy response and copper homoeostasis is linked by AMPK phosphorylating and stabilising CTR1, which provides a promising strategy to combat breast cancer by combining AMPK agonists and copper chelators.
Sections du résumé
BACKGROUND
Predominant roles of copper and its transporter, copper transporter 1 (CTR1), in tumorigenesis have been explored recently; however, the upstream regulation of CTR1 and combinational intervention of copper chelators in malignancies remain largely unclear.
METHODS
CRISPR/Cas9-based kinome screening was used to identify the CTR1 upstream kinases. Immunofluorescence assays were utilised to detect CTR1 localisation. In vitro kinase assays and mass spectrometry were performed to detect CTR1 phosphorylation. Ubiquitination assays were performed to validate CTR1 stability. Colony formation, EdU labelling, Annexin V-FITC/PI-based apoptosis assays were carried out to detect the drug effect on cell growth and apoptosis. Xenografted mouse models were employed to investigate drug effects in vivo.
RESULTS
We identify that CTR1 undergoes AMPK-mediated phosphorylation, which enhances CTR1 stabilisation and membrane translocation by affecting Nedd4l interaction, resulting in increased oncogenic roles in breast cancer. Importantly, activation of AMPK with its agonist metformin markedly enhances CTR1 levels, and leads to the combinational usage of AMPK agonists and copper chelators for breast cancer treatment.
CONCLUSIONS
Our findings not only reveal the crosstalk between energy response and copper uptake via AMPK-mediated CTR1 phosphorylation and stability but also highlight the strategy to combat breast cancer by a combination of AMPK agonists and copper chelators.
SIGNIFICANCE
The connection between energy response and copper homoeostasis is linked by AMPK phosphorylating and stabilising CTR1, which provides a promising strategy to combat breast cancer by combining AMPK agonists and copper chelators.
Identifiants
pubmed: 36807336
doi: 10.1038/s41416-022-02127-4
pii: 10.1038/s41416-022-02127-4
pmc: PMC10070418
doi:
Substances chimiques
Copper Transporter 1
0
AMP-Activated Protein Kinases
EC 2.7.11.31
Copper
789U1901C5
Metformin
9100L32L2N
Cation Transport Proteins
0
Chelating Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1452-1465Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321:288–300.
pubmed: 30667505
doi: 10.1001/jama.2018.19323
Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389:2430–42.
pubmed: 27939063
doi: 10.1016/S0140-6736(16)32454-0
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48.
pubmed: 21067385
doi: 10.1056/NEJMra1001389
Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19:5533–40.
pubmed: 23948975
doi: 10.1158/1078-0432.CCR-13-0799
Winters S, Martin C, Murphy D, Shokar NK. Breast cancer epidemiology, prevention, and screening. Prog Mol Biol Transl Sci. 2017;151:1–32.
pubmed: 29096890
doi: 10.1016/bs.pmbts.2017.07.002
Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Prim. 2019;5:66.
pubmed: 31548545
doi: 10.1038/s41572-019-0111-2
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21.
pubmed: 30345906
doi: 10.1056/NEJMoa1809615
Feng Y, Zeng JW, Ma Q, Zhang S, Tang J, Feng JF. Serum copper and zinc levels in breast cancer: a meta-analysis. J Trace Elem Med Biol. 2020;62:126629.
pubmed: 32745979
doi: 10.1016/j.jtemb.2020.126629
Lopez J, Ramchandani D, Vahdat L. Copper depletion as a therapeutic strategy in cancer. Met Ions Life Sci. 2019;19.
Myint ZW, Oo TH, Thein KZ, Tun AM, Saeed H. Copper deficiency anemia: review article. Ann Hematol. 2018;97:1527–34.
pubmed: 29959467
doi: 10.1007/s00277-018-3407-5
Brady DC, Crowe MS, Turski ML, Hobbs GA, Yao X, Chaikuad A, et al. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature. 2014;509:492–6.
pubmed: 24717435
pmcid: 4138975
doi: 10.1038/nature13180
Guo J, Cheng J, Zheng N, Zhang X, Dai X, Zhang L, et al. Copper promotes tumorigenesis by activating the PDK1-AKT oncogenic pathway in a copper transporter 1 dependent manner. Adv Sci (Weinh). 2021;8:e2004303.
pubmed: 34278744
doi: 10.1002/advs.202004303
Tsang T, Posimo JM, Gudiel AA, Cicchini M, Feldser DM, Brady DC. Copper is an essential regulator of the autophagic kinases ULK1/2 to drive lung adenocarcinoma. Nat Cell Biol. 2020;22:412–24.
pubmed: 32203415
pmcid: 7610258
doi: 10.1038/s41556-020-0481-4
Voli F, Valli E, Lerra L, Kimpton K, Saletta F, Giorgi FM, et al. Intratumoral copper modulates PD-L1 expression and influences tumor immune evasion. Cancer Res. 2020;80:4129–44.
pubmed: 32816860
doi: 10.1158/0008-5472.CAN-20-0471
Rieber M. Cancer pro-oxidant therapy through copper redox cycling: repurposing disulfiram and tetrathiomolybdate. Curr Pharm Des. 2020;26:4461–6.
pubmed: 32600223
doi: 10.2174/1381612826666200628022113
Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. Trends Endocrinol Metab. 2013;24:469–80.
pubmed: 23773243
doi: 10.1016/j.tem.2013.05.004
Rattan R, Giri S, Singh AK, Singh I. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem. 2005;280:39582–93.
pubmed: 16176927
doi: 10.1074/jbc.M507443200
Lee YK, Park OJ. Regulation of mutual inhibitory activities between AMPK and Akt with quercetin in MCF-7 breast cancer cells. Oncol Rep. 2010;24:1493–7.
pubmed: 21042744
Ponnusamy L, Natarajan SR, Thangaraj K, Manoharan R. Therapeutic aspects of AMPK in breast cancer: progress, challenges, and future directions. Biochim Biophys Acta Rev Cancer. 2020;1874:188379.
pubmed: 32439311
doi: 10.1016/j.bbcan.2020.188379
Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27:3297–302.
pubmed: 19487376
pmcid: 2736070
doi: 10.1200/JCO.2009.19.6410
Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8:2031–40.
pubmed: 19440038
doi: 10.4161/cc.8.13.8814
Lega IC, Fung K, Austin PC, Lipscombe LL. Metformin and breast cancer stage at diagnosis: a population-based study. Curr Oncol. 2017;24:e85–e91.
pubmed: 28490930
pmcid: 5407883
doi: 10.3747/co.24.3380
Scherbakov AM, Sorokin DV, Tatarskiy VV Jr, Prokhorov NS, Semina SE, Berstein LM, et al. The phenomenon of acquired resistance to metformin in breast cancer cells: the interaction of growth pathways and estrogen receptor signaling. IUBMB Life. 2016;68:281–92.
pubmed: 26892736
doi: 10.1002/iub.1481
Jiang Q, Zheng N, Bu L, Zhang X, Zhang X, Wu Y, et al. SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions. Mol Cancer. 2021;20:100.
pubmed: 34353330
pmcid: 8340461
doi: 10.1186/s12943-021-01397-5
Bertinato J, L’Abbe MR. Copper modulates the degradation of copper chaperone for Cu,Zn superoxide dismutase by the 26 S proteosome. J Biol Chem. 2003;278:35071–8.
pubmed: 12832419
doi: 10.1074/jbc.M302242200
West EC, Prohaska JR. Cu,Zn-superoxide dismutase is lower and copper chaperone CCS is higher in erythrocytes of copper-deficient rats and mice. Exp Biol Med (Maywood). 2004;229:756–64.
pubmed: 15337829
doi: 10.1177/153537020422900807
Caruano-Yzermans AL, Bartnikas TB, Gitlin JD. Mechanisms of the copper-dependent turnover of the copper chaperone for superoxide dismutase. J Biol Chem. 2006;281:13581–7.
pubmed: 16531609
doi: 10.1074/jbc.M601580200
Herzig S, Shaw RJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol. 2018;19:121–35.
pubmed: 28974774
doi: 10.1038/nrm.2017.95
Clifford RJ, Maryon EB, Kaplan JH. Dynamic internalization and recycling of a metal ion transporter: Cu homeostasis and CTR1, the human Cu(+) uptake system. J Cell Sci. 2016;129:1711–21.
pubmed: 26945057
pmcid: 4852764
Puig S, Thiele DJ. Molecular mechanisms of copper uptake and distribution. Curr Opin Chem Biol. 2002;6:171–80.
pubmed: 12039001
doi: 10.1016/S1367-5931(02)00298-3
Maryon EB, Molloy SA, Zimnicka AM, Kaplan JH. Copper entry into human cells: progress and unanswered questions. Biometals. 2007;20:355–64.
pubmed: 17211679
doi: 10.1007/s10534-006-9066-3
Mandal T, Kar S, Maji S, Sen S, Gupta A. Structural and functional diversity among the members of CTR, the membrane copper transporter family. J Membr Biol. 2020;253:459–68.
pubmed: 32975619
pmcid: 7611187
doi: 10.1007/s00232-020-00139-w
Nose Y, Wood LK, Kim BE, Prohaska JR, Fry RS, Spears JW, et al. Ctr1 is an apical copper transporter in mammalian intestinal epithelial cells in vivo that is controlled at the level of protein stability. J Biol Chem. 2010;285:32385–92.
pubmed: 20699218
pmcid: 2952240
doi: 10.1074/jbc.M110.143826
Petris MJ, Smith K, Lee J, Thiele DJ. Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1. J Biol Chem. 2003;278:9639–46.
pubmed: 12501239
doi: 10.1074/jbc.M209455200
Trefts E, Shaw RJ. AMPK: restoring metabolic homeostasis over space and time. Mol Cell. 2021;81:3677–90.
pubmed: 34547233
pmcid: 8549486
doi: 10.1016/j.molcel.2021.08.015
Cheng J, Zhang T, Ji H, Tao K, Guo J, Wei W. Functional characterization of AMP-activated protein kinase signaling in tumorigenesis. Biochim Biophys Acta. 2016;1866:232–51.
pubmed: 27681874
pmcid: 5483337
Amano T, Nakamizo A, Mishra SK, Gumin J, Shinojima N, Sawaya R, et al. Simultaneous phosphorylation of p53 at serine 15 and 20 induces apoptosis in human glioma cells by increasing expression of pro-apoptotic genes. J Neurooncol. 2009;92:357–71.
pubmed: 19357962
doi: 10.1007/s11060-009-9844-1
Faria J, Negalha G, Azevedo A, Martel F. Metformin and breast cancer: molecular targets. J Mammary Gland Biol Neoplasia. 2019;24:111–23.
pubmed: 30903363
doi: 10.1007/s10911-019-09429-z
De A, Kuppusamy G. Metformin in breast cancer: preclinical and clinical evidence. Curr Probl Cancer. 2020;44:100488.
pubmed: 31235186
doi: 10.1016/j.currproblcancer.2019.06.003
Sammons S, Brady D, Vahdat L, Salama AK. Copper suppression as cancer therapy: the rationale for copper chelating agents in BRAF(V600) mutated melanoma. Melanoma Manag. 2016;3:207–16.
pubmed: 30190890
pmcid: 6094647
doi: 10.2217/mmt-2015-0005
Xu M, Casio M, Range DE, Sosa JA, Counter CM. Copper chelation as targeted therapy in a mouse model of oncogenic BRAF-driven papillary thyroid cancer. Clin Cancer Res. 2018;24:4271–81.
pubmed: 30065097
pmcid: 6125179
doi: 10.1158/1078-0432.CCR-17-3705
Ramchandani D, Berisa M, Tavarez DA, Li Z, Miele M, Bai Y, et al. Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis. Nat Commun. 2021;12:7311.
pubmed: 34911956
pmcid: 8674260
doi: 10.1038/s41467-021-27559-z
Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642–6.
pubmed: 16308421
pmcid: 3074427
doi: 10.1126/science.1120781
Snima KS, Pillai P, Cherian AM, Nair SV, Lakshmanan VK. Anti-diabetic drug metformin: challenges and perspectives for cancer therapy. Curr Cancer Drug Targets. 2014;14:727–36.
pubmed: 25329671
doi: 10.2174/1568009614666141020105502
Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6:91–9.
pubmed: 15261145
doi: 10.1016/j.ccr.2004.06.007
Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA. 2004;101:3329–35.
pubmed: 14985505
pmcid: 373461
doi: 10.1073/pnas.0308061100
Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature. 2012;485:661–5.
pubmed: 22660331
pmcid: 3607316
doi: 10.1038/nature11066
Laderoute KR, Amin K, Calaoagan JM, Knapp M, Le T, Orduna J, et al. 5’-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol. 2006;26:5336–47.
pubmed: 16809770
pmcid: 1592699
doi: 10.1128/MCB.00166-06
Saito Y, Chapple RH, Lin A, Kitano A, Nakada D. AMPK protects leukemia-initiating cells in myeloid leukemias from metabolic stress in the bone marrow. Cell Stem Cell. 2015;17:585–96.
pubmed: 26440282
pmcid: 4597792
doi: 10.1016/j.stem.2015.08.019
Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma. Mol Cancer Ther. 2003;2:617–22.
pubmed: 12883034
Das A, Ash D, Fouda AY, Sudhahar V, Kim YM, Hou Y, et al. Cysteine oxidation of copper transporter CTR1 drives VEGFR2 signalling and angiogenesis. Nat Cell Biol. 2022;24:35–50.
pubmed: 35027734
pmcid: 8851982
doi: 10.1038/s41556-021-00822-7
Wu Y, Zhou L, Wang X, Lu J, Zhang R, Liang X, et al. A genome-scale CRISPR-Cas9 screening method for protein stability reveals novel regulators of Cdc25A. Cell Discov. 2016;2:16014.
pubmed: 27462461
pmcid: 4877570
doi: 10.1038/celldisc.2016.14
Domon B, Aebersold R. Mass spectrometry and protein analysis. Science. 2006;312:212–7.
pubmed: 16614208
doi: 10.1126/science.1124619